NEW YORK – Centogene and Molecular Health said on Monday that they have signed an exclusive collaboration deal to help develop new orphan drugs, starting with epilepsy as the first indication.
Under the agreement, the firms will combine real-life data sets in rare diseases from Centogene with Molecular Health's expertise in big data, artificial intelligence, and computational algorithms in a project called Real-life data and Innovative Bioinformatic Algorithms (RIBA).